Similar articles for PMID: 21296187

Year	Number of Results
1972	1
1975	1
1996	1
1999	1
2000	2
2001	2
2002	3
2003	8
2004	2
2005	2
2006	3
2008	3
2009	2
2010	5
2011	11
2012	7
2013	7
2014	14
2015	7
2016	5
2017	3
2018	2
2019	8
2020	1
2021	3
2022	1
2023	1
2024	0

1

Risk of nonmelanoma skin cancer in patients with inflammatory bowel disease who use thiopurines is not increased.

van Schaik FD, van Oijen MG, Smeets HM, van der Heijden GJ, Siersema PD, Oldenburg B. van Schaik FD, et al. Clin Gastroenterol Hepatol. 2011 May;9(5):449-50.e1; author reply 450-1. doi: 10.1016/j.cgh.2011.01.021. Epub 2011 Feb 4. Clin Gastroenterol Hepatol. 2011. PMID: 21296187 No abstract available.

2

Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased.

Peyrin-Biroulet L, Chevaux JB, Bouvier AM, Carrat F, Beaugerie L. Peyrin-Biroulet L, et al. Am J Gastroenterol. 2012 Sep;107(9):1443-4. doi: 10.1038/ajg.2012.181. Am J Gastroenterol. 2012. PMID: 22951883 No abstract available.

3

Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis.

Ariyaratnam J, Subramanian V. Ariyaratnam J, et al. Am J Gastroenterol. 2014 Feb;109(2):163-9. doi: 10.1038/ajg.2013.451. Epub 2014 Jan 14. Am J Gastroenterol. 2014. PMID: 24419479 Review.

4

What's good for the goose should be good for the gander--6-MP use in fathers with inflammatory bowel disease.

Kane SV. Kane SV. Am J Gastroenterol. 2000 Mar;95(3):581-2. doi: 10.1111/j.1572-0241.2000.01828.x. Am J Gastroenterol. 2000. PMID: 10710042 No abstract available.

5

Thiopurines best practice.

Friedman A. Friedman A. J Gastroenterol Hepatol. 2016 Jun;31 Suppl 1:6-7. doi: 10.1111/jgh.13345. J Gastroenterol Hepatol. 2016. PMID: 26990458 No abstract available.

6

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.

Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P, Hugot JP, Lémann M, Nahon S, Sabaté JM, Tucat G, Beaugerie L; Cesame Study Group. Peyrin-Biroulet L, et al. Gastroenterology. 2011 Nov;141(5):1621-28.e1-5. doi: 10.1053/j.gastro.2011.06.050. Epub 2011 Jun 25. Gastroenterology. 2011. PMID: 21708105

7

Optimization and individualization of thiopurine therapy in inflammatory bowel disease: the great variability among drug responses.

Scherl E, Subbaramiah K. Scherl E, et al. Pharmacogenomics J. 2003;3(2):66-8. doi: 10.1038/sj.tpj.6500162. Pharmacogenomics J. 2003. PMID: 12746731 No abstract available.

8

Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.

Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, Loftus EV Jr, Peyrin-Biroulet L, Blonski WC, Van Domselaar M, Chaparro M, Sandilya S, Bewtra M, Beigel F, Biancone L, Lichtenstein GR. Kotlyar DS, et al. Clin Gastroenterol Hepatol. 2015 May;13(5):847-58.e4; quiz e48-50. doi: 10.1016/j.cgh.2014.05.015. Epub 2014 May 28. Clin Gastroenterol Hepatol. 2015. PMID: 24879926

9

Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.

Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Long MD, et al. Gastroenterology. 2012 Aug;143(2):390-399.e1. doi: 10.1053/j.gastro.2012.05.004. Epub 2012 May 11. Gastroenterology. 2012. PMID: 22584081 Free PMC article.

10

[Optimized thiopurine treatment in chronic inflammatory bowel disease].

Kiszka-Kanowitz M, Theede K, Nielsen AM. Kiszka-Kanowitz M, et al. Ugeskr Laeger. 2015 Jun 22;177(26):1253-5. Ugeskr Laeger. 2015. PMID: 26550625 Review. Danish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

91 results

Results by year